The Batlle Lab
@batllelab.bsky.social
We work on minimal residual disease and metastasis by colorectal cancer from the perspective of cancer stem cells and their interaction with the tumor microenvironment.
@IRBBarcelona,bsky.social
@IRBBarcelona,bsky.social
8/17
Meanwhile, aPD-L1 did something remarkable but incomplete: it boosted T cell motility allowing infiltrated cells to move and engage targets.
TGFβ inhibition enabled their entry but not their movement.
✅Only combination therapy achieved both, unleashing a fully active antitumor immune response
Meanwhile, aPD-L1 did something remarkable but incomplete: it boosted T cell motility allowing infiltrated cells to move and engage targets.
TGFβ inhibition enabled their entry but not their movement.
✅Only combination therapy achieved both, unleashing a fully active antitumor immune response
November 7, 2025 at 12:30 PM
8/17
Meanwhile, aPD-L1 did something remarkable but incomplete: it boosted T cell motility allowing infiltrated cells to move and engage targets.
TGFβ inhibition enabled their entry but not their movement.
✅Only combination therapy achieved both, unleashing a fully active antitumor immune response
Meanwhile, aPD-L1 did something remarkable but incomplete: it boosted T cell motility allowing infiltrated cells to move and engage targets.
TGFβ inhibition enabled their entry but not their movement.
✅Only combination therapy achieved both, unleashing a fully active antitumor immune response
➡️ This important video was missing from yesterday’s #Bluetorial.
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
October 24, 2025 at 6:47 AM
➡️ This important video was missing from yesterday’s #Bluetorial.
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR